HRP20080677T3 - Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease - Google Patents

Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease

Info

Publication number
HRP20080677T3
HRP20080677T3 HR20080677T HRP20080677T HRP20080677T3 HR P20080677 T3 HRP20080677 T3 HR P20080677T3 HR 20080677 T HR20080677 T HR 20080677T HR P20080677 T HRP20080677 T HR P20080677T HR P20080677 T3 HRP20080677 T3 HR P20080677T3
Authority
HR
Croatia
Prior art keywords
dihydrotetrabenazine
huntington
cis
disease
symptons
Prior art date
Application number
HR20080677T
Other languages
English (en)
Croatian (hr)
Inventor
Tridgett Robert
Filloux T.
Original Assignee
Cambridge Laboratories (Ireland) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Laboratories (Ireland) Limited filed Critical Cambridge Laboratories (Ireland) Limited
Publication of HRP20080677T3 publication Critical patent/HRP20080677T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20080677T 2005-07-14 2008-12-29 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease HRP20080677T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514501.6A GB0514501D0 (en) 2005-07-14 2005-07-14 Pharmaceutical compounds
PCT/GB2006/002593 WO2007007105A1 (en) 2005-07-14 2006-07-13 Use of 3,1ib-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease

Publications (1)

Publication Number Publication Date
HRP20080677T3 true HRP20080677T3 (en) 2009-02-28

Family

ID=34897233

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080677T HRP20080677T3 (en) 2005-07-14 2008-12-29 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptons of huntington' s disease

Country Status (24)

Country Link
US (1) US20080319000A1 (ja)
EP (2) EP2027861B1 (ja)
JP (1) JP2009501202A (ja)
KR (1) KR20080030666A (ja)
CN (1) CN101282726A (ja)
AT (2) ATE409481T1 (ja)
AU (1) AU2006268098B2 (ja)
CA (1) CA2615077A1 (ja)
CY (1) CY1108653T1 (ja)
DE (1) DE602006002982D1 (ja)
DK (1) DK1885363T3 (ja)
ES (1) ES2314931T3 (ja)
GB (1) GB0514501D0 (ja)
HK (1) HK1111085A1 (ja)
HR (1) HRP20080677T3 (ja)
ME (1) ME01629B (ja)
NZ (1) NZ565522A (ja)
PL (1) PL1885363T3 (ja)
PT (1) PT1885363E (ja)
RS (1) RS50626B (ja)
RU (1) RU2409365C2 (ja)
SI (1) SI1885363T1 (ja)
WO (1) WO2007007105A1 (ja)
ZA (1) ZA200800905B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2771539A1 (en) * 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
CN103003275A (zh) * 2010-06-01 2013-03-27 奥斯拜客斯制药有限公司 Vmat2的苯并喹啉酮抑制剂
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
JP7250692B2 (ja) * 2017-04-01 2023-04-03 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療における使用のためのジヒドロテトラベナジン
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201808464D0 (en) * 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
KR20220066253A (ko) * 2019-07-16 2022-05-24 러쉬 유니버시티 메디컬 센터 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US3123609A (en) * 1964-03-03 Benzo
US3009918A (en) * 1961-11-21 Chz ch
US3132147A (en) * 1964-05-05
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3159638A (en) * 1964-12-01 Xcha-chj
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
JPS4836303B1 (ja) * 1968-12-27 1973-11-02
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NO166268C (no) * 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2001079198A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
WO2006053067A2 (en) * 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma

Also Published As

Publication number Publication date
CA2615077A1 (en) 2007-01-18
SI1885363T1 (sl) 2009-02-28
EP2027861B1 (en) 2011-08-31
PT1885363E (pt) 2009-01-08
KR20080030666A (ko) 2008-04-04
EP1885363A1 (en) 2008-02-13
CY1108653T1 (el) 2014-04-09
JP2009501202A (ja) 2009-01-15
AU2006268098B2 (en) 2011-02-17
ZA200800905B (en) 2010-04-28
NZ565522A (en) 2010-04-30
RU2008105590A (ru) 2009-08-20
EP1885363B1 (en) 2008-10-01
RS50626B (sr) 2010-06-30
ES2314931T3 (es) 2009-03-16
CN101282726A (zh) 2008-10-08
ATE409481T1 (de) 2008-10-15
EP2027861A1 (en) 2009-02-25
ME01629B (me) 2010-06-30
US20080319000A1 (en) 2008-12-25
WO2007007105A1 (en) 2007-01-18
DK1885363T3 (da) 2008-12-08
AU2006268098A1 (en) 2007-01-18
RU2409365C2 (ru) 2011-01-20
PL1885363T3 (pl) 2009-05-29
ATE522215T1 (de) 2011-09-15
DE602006002982D1 (de) 2008-11-13
HK1111085A1 (en) 2008-08-01
GB0514501D0 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
ME01629B (me) Upotreba 3,11 b-cis-dihidrotetrabenazina za tretman simptoma huntington-ove bolesti
CY1121408T1 (el) Προληψη και θεραπεια συνουκλεϊνοπαθειας και αμυλοειδοπαθειας
HK1215960A1 (zh) 用於治療視網膜變性疾病的改良方式
EP1802303A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING A-SYNUCLEIN TOXICITY
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006091693A3 (en) Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
WO2005105129A3 (en) Epitopes related to coeliac disease
IL176393A0 (en) Patterned laser treatment of the retina
UA94580C2 (ru) Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием
WO2008103472A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
HK1110768A1 (en) 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
DK1732648T3 (da) Sygdomsbehandling
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
WO2007054566A3 (en) Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy